X0206 3 2018-05-02 0 0001463361 Unity Biotechnology, Inc. UBX 0001544443 ARCH Venture Partners VII, LLC 8755 W. HIGGINS RD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001544444 ARCH Venture Partners VII, L.P. 8755 W. HIGGINS ROAD SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001402439 Arch Venture Fund VII LP 8755 W HIGGINS SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001616165 ARCH Venture Partners VIII, LLC C/O ARCH VENTURE PARTNERS VIII, LLC 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001617237 ARCH Venture Fund VIII Overage, L.P. C/O ARCH VENTURE PARTNERS VIII, LLC 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001219042 NELSEN ROBERT C/O ARCH VENTURE PARTNERS 8755 W. HIGGINS RD, SUITE 1025 CHICAGO IL 60631 1 0 0 0 0001219039 CRANDELL KEITH C/O ARCH VENTURE PARTNERS VIII, LLC 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001219043 BYBEE CLINTON C/O ARCH VENTURE PARTNERS VIII, LLC 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 Common Stock 39547 I See Footnote Series A-1 Preferred Stock Common Stock 2030625 I See Footnote Series A-2 Preferred Stock Common Stock 4228432 I See Footnote Series B Preferred Stock Common Stock 2067160 I See Footnote Series B Preferred Stock Common Stock 1486745 I See Footnote Series C Preferred Stock Common Stock 195672 I See Footnote The shares of the Issuer's Preferred Stock automatically convert into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. The expiration date is not relevant to the conversion of these securities. The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC and AVP GPLLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. ARCH Venture Fund VII, L.P., By: ARCH Venture Partners VII, L.P., its General Partner, By: ARCH Venture Partners VII, LLC, its General Partner, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 2018-05-02 ARCH Venture Fund VIII Overage, L.P., ARCH Venture Partners VIII, LLC, its General Partner, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 2018-05-02 RCH Venture Partners VII, L.P., By: ARCH Venture Partners VII, LLC, its General Partner, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 2018-05-02 ARCH Venture Partners VII, LLC, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 2018-05-02 ARCH Venture Partners VIII, LLC, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 2018-05-02 Keith Crandell, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact 2018-05-02 Clinton Bybee, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact 2018-05-02 Robert Nelsen, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact 2018-05-02